PatientsVille.com Logo

Post-traumatic and Lorazepam

PatientsVille

Post-traumatic Symptoms and Causes

Post-traumatic stress disorder (PTSD) is a real illness. You can get PTSD after living through or seeing a traumatic event, such as war, a hurricane, sexual assault, physical abuse, or a bad accident. PTSD makes you feel stressed and afraid after the danger is over. It affects your life and the people around you.

PTSD can cause problems like

  • Flashbacks, or feeling like the event is happening again
  • Trouble sleeping or nightmares
  • Feeling alone
  • Angry outbursts
  • Feeling worried, guilty, or sad

PTSD starts at different times for different people. Signs of PTSD may start soon after a frightening event and then continue. Other people develop new or more severe signs months or even years later. PTSD can happen to anyone, even children.

Treatment may include talk therapy, medicines, or both. Treatment might take 6 to 12 weeks. For some people, it takes longer.

NIH: National Institute of Mental Health

Check out the latest treatments for post-traumatic

post-traumatic treatment research studies

Lorazepam clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lorazepam Side Effects

Completed Suicide (220)
Somnolence (138)
Poisoning (137)
Suicide Attempt (121)
Overdose (105)
Anxiety (104)
Agitation (100)
Tachycardia (84)
Cardiac Arrest (81)
Confusional State (80)
Nausea (79)
Respiratory Arrest (73)
Dizziness (70)
Coma (68)
Sopor (68)
Hypotension (66)
Fall (66)
Toxicity To Various Agents (65)
Intentional Overdose (64)
Dyspnoea (61)
Fatigue (57)
Vomiting (56)
Depression (56)
Insomnia (56)
Cardio-respiratory Arrest (55)
Death (55)
Sedation (52)
Headache (49)
Loss Of Consciousness (48)
Asthenia (45)
Convulsion (45)
Diarrhoea (43)
Metabolic Acidosis (42)
Condition Aggravated (39)
Tremor (37)
Pyrexia (34)
Product Substitution Issue (34)
Unresponsive To Stimuli (34)
Suicidal Ideation (33)
Psychotic Disorder (33)
Feeling Abnormal (33)
Catatonia (33)
Pain (33)
Gait Disturbance (32)
Disorientation (31)
Respiratory Failure (31)
Syncope (30)
Malaise (30)
Depressed Level Of Consciousness (29)
Oxygen Saturation Decreased (29)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Feeling apathetic, lack of interest in anything. Not sure if it is my emotional state or because of lorazepam

Hi can I join the royal marines if I did 14 weeks in the army and left due to depression and suicidal thoughts and I admitted to smoking cannabis on my drug test after my 2 weeks leave, I really want to know because I am built for the military and it

Hi, i was on loraezpam for anxiety attacks and was having some side affects off of it and stopped taking it.i was taking it for about a month or less. it made me feel more depressed then i was. how long does it take to get out of the system?

Look plain and simple this drug is no joke, I don't work for anybody in relation to this post.. I'm just your normal everyday person with crap salary. Ive been taking Propecia since I was 22 I didn't start having problems until I

14 month old girl developed erythematous skin lasion on left cheek 5 days post prevnar vaccine. 24 hrs later lesion weeping straw colored fluid and crusted. seen at pediatrician 7 days post prevnar vaccine and also diagnosed with ear infection. Start

20mg is a lot. I've heard that some doctors ramp you up to 20 when it is totally unnecessary. I can identify with the sleepiness and I was only on 10. Read my post below about switching to 5, but don't do it without talking to you

4 months post dysport injection and still unable to speak correctly. Drooping on one side of face, eyes still not normal, hard to recognize myself as my eyes were big and now they look to be about half the size. Entire face looks flattened. When w

48YO male, obese, diabetic, hypertensive, mild anxiety and depression. R BKA, R Acetabula fracture 13 years ago from motorcycle accident. Swollen gall bladder removed during hospitalization. Current meds include Metformin (withheld pre- and post- ct)

54y/o, WM, Status post quadruple coronary artery bypass graft surgery(10 months ago). Surgery went well, only complication was a pretty large left pleural effusion requiring chest tube placement. Resolved well, no further problems

62 year old male. Velcade was a great treatment for my Multiple Myaloma, however the post treatment side effects have been bothersum and painful. My feet feel like they have pins stuck in them. In the last month it has spread from my toes to the bott

A 40-year-old manager, at a prominent legal firm in L.A., experiences abdominal pain post lunch. He goes to the restroom a couple of times, but continues to experience pain and cramps. He eventually decides to get himself examined. While questioning

After 1st dose, headache, aches, fatigue, severe vomiting and general unwell feeling for 3 weeks post. After 2nd injection same indications but not as intense, although severe fatigue. I am concerned about my next injection in 4 months!

Also one other thing. Please post which Mucinex you tried. There is regular Mucinex, Mucinex-D or Mucinex DM. The DM is for the<a href='http://www.google.com/search?hl=en&amp;client=safari&amp;rls=en&amp;

Post-traumatic Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: Patient Satisfaction for Bronchoscopy
Interventions: Drug: Lorazepam;   Drug: Control
Outcome Measures: patient satisfaction;   relationship between patient satisfaction and sleep quality, anxiety level
2 Unknown  Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: Healthy Subjects
Interventions: Drug: Lorazepam;   Drug: Placebo
Outcome Measures: Correlated Brain Activity using MEG and SNI analysis;   Correlated Brain Activity using MEG and standard analyses
3 Unknown  IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Agitation
Interventions: Drug: IM olanzapine;   Drug: haloperidol plus Lorazepam IM
Outcome Measures: Positive and Negative Symptom Scale Excited Component (PANSS-EC);   Agitation-Calmness Evaluation Scale (ACES)
4 Recruiting Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Lorazepam;   Drug: Placebo;   Drug: Haloperidol decanoate;   Behavioral: Questionnaires
Outcome Measure: Control of Delirium Symptoms
5 Recruiting Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: Status Epilepticus;   Epilepsy
Interventions: Drug: Clonazepam;   Drug: Fosphenytoin;   Drug: Placebo;   Drug: Lorazepam
Outcome Measures: Percentage of patient with a cessation of seizures and absence of recurrence;   Duration between the first cessation and the recurrence of seizures;   Percentage of patients having had a second injection of benzodiazepine;   Percentage of patients having had an injection of the second line treatment;   Percentage of patients having a general anesthesia for refractory status epilepticus;   Percentage of patients having had a side effect;   Percentage of patients having been mechanically ventilated;   Glasgow Coma Scale;   Mortality;   Length of stay in Intensive Care Unit;   Length of stay in hospital
6 Recruiting The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: Alzheimer's Disease (AD)
Intervention: Drug: Lorazepam
Outcome Measures: AVLT Long term memory score;   Groton Maze Learning Test (GMLT) score
7 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: Healthy Volunteers
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
8 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: Volunteers Aged Between 65 and 75 Years Old
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
9 Not yet recruiting Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: Epilepsia Partialis Continua;   Kojewnikov's Epilepsy;   Epilepsy
Interventions: Drug: Clobazam;   Drug: Clonazepam;   Drug: Lorazepam
Outcome Measures: Time (measured in minutes) to onset of seizure freedom;   Reduction of seizure frequency/minute;   Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale;   Ambulatory function as measured by the Hauser Ambulation Index
10 Recruiting Characterizing and Predicting Drug Effects on Cognition
Condition: Cognitive Deficits
Interventions: Drug: Topiramate;   Drug: Lorazepam
Outcome Measures: Relationship between neurocognitive performance and study drug plasma concentration;   Neurophysiological effect of study drug on working memory
11 Recruiting Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: Liver Fibrosis;   Alpha-1 Antitrypsin Deficiency;   AAT Deficiency;   AATD
Interventions: Device: Abdominal ultrasound;   Procedure: History and physical;   Procedure: Intravenous catheter;   Procedure: Blood draw;   Other: Liver questionnaire;   Procedure: Liver Biopsy;   Drug: Midazolam;   Drug: Fentanyl;   Drug: Lidocaine;   Drug: Acetaminophen;   Drug: Lorazepam;   Drug: Oxycodone/Acetaminophen;   Drug: Ondansetron
Outcome Measures: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.;   To identify environmental and host risk factors for clinically significant liver fibrosis.;   To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.;   To explore epigenetic markers for the development of liver fibrosis.;   To quantify liver fibrosis progression.
12 Recruiting Sedative Premedication: Efficacy On Patient Experience
Condition: Perioperative Anxiety
Interventions: Drug: Lorazepam;   Other: no premedication;   Drug: Placebo (microcrystalline celluloses)
Outcome Measures: the EVAN score;   the perioperative level of anxiety
13 Not yet recruiting Explanation About Sleep in Post Trauma Patients
Conditions: Post Traumatic Stress Disorder;   Sleep Deprivation
Interventions: Behavioral: Explanation encouraging sleep;   Behavioral: Explanation discouraging sleep;   Drug: Lorazepam
Outcome Measure: PTSD severity as measured by CAPS
14 Recruiting Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: Dental Care for Disabled
Interventions: Drug: Midazolam Mylan;   Drug: Lorazepam Mylan;   Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Outcome Measures: Level of cooperation of patient when receiving regular dental care;   Recording of vital parameters during regular dental care delivery;   Level of patient comfort and possible side-effects after dental treatment session
15 Recruiting A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: Healthy
Interventions: Drug: PF-06372865 or Placebo;   Drug: PF-06372865 or Placebo or Lorazepam
Outcome Measures: Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Area Under the Curve From Time Zero to Extrapolated Infinite Time;   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Area Under the Curve From Time Zero to 24 hours;   Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy);   Change in Body Sway;   Change in Smooth Pursuit;   Change in Bond and Lader VAS;   Change in Adaptive Tracking;   Change in Visual Verbal Learning Test;   Change in Pharmaco-EEG
16 Unknown  Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: Critical Illness;   Mechanical Ventilation Complication
Interventions: Procedure: Enteral Sedation (EN);   Procedure: Control group: Intravenous Sedation (IV)
Outcome Measures: Percent of efficacy, measured by observed RASS = desired RASS ± 1.;   Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.;   Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11);   Ventilation free days (12);   Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13);   Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.;   Sedative drugs costs.;   Indirect inefficacy markers
17 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: Alcohol Withdrawal Delirium;   Alcohol Withdrawal Associated Autonomic Hyperactivity;   Alcohol Withdrawal Hallucinosis;   Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
18 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
19 Recruiting TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: Cardiac Arrest;   Postanoxic Encephalopathy;   Status Epilepticus
Interventions: Drug: Anti-epileptic drugs;   Other: No anti-epileptic drugs
Outcome Measures: Neurological outcome;   Long term outcome
20 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)